Answers are grounded in this paper and cite their sources.
Background: In January 2023, EMA's CHMP endorsed the Pharmacovigilance Risk Assessment Committee's (PRAC) measures for Janus kinase inhibitors (JAKi), addressing serious side effects in treating chronic inflammatory conditions, including Rheumatoid Arthritis (RA). The use of these medications is now restricted in specific high risk patients including, but not limited to, those aged 65 years or older, those with specific cardiovascular comorbidities, smokers, and those at higher risk of developing malignancies. Caution is advised among patients in these risk categories and JAKi doses should be reduced based on an individuals risk. Objectives: Real-world patient data was used to investigate the impact of the PRAC announcement on patients with Rheumatoid Arthritis and physicians' JAKi prescribing patterns. Methods: Informed consent was obtained from 228 Rheumatologists across the main 5 European markets: France, Germany, Italy, Spain, and United Kingdom (EU5). They provided 1593 anonymised patient record forms (PRF) for RA patients on an advanced therapy (AT) in the Research Partnership's Q4 2023 Therapy Watch Rheumatology study. The data is weighted based on physicians' proportions of dynamic (initiated or switched AT in the last 3 months) and stable patients, where each physician has an individual weight factor. Results: Of the 1593 patients, 50% had at least one PRAC risk factor. 14% of patients were aged ≥ 65 years old, whilst 35% had at least one CV risk factor. The prevalence of current smokers stood at ~11%, former smokers who quit <5 years ago amounted to ~2%, those who quit 5-10 years ago accounted for ~5%, and those who quit >10 years ago represented ~3%. Comparably, the proportion of patients with a high risk of cancer was 8%. The biggest difference in JAKi market share was among individuals with a CV risk, where JAKis market share reported a decline (15%) vs. Q1 2023. However, JAKi prescribing has remained stable among patients ≥ 65 years old. Conclusion: Of those patients who fall under the PRAC warning, the greatest proportion do so due to one or more CV risk factors. Patients over 65 years old represent a small Rheumatoid Arthritis patient population at risk when using JAKi. Our findings suggest the PRAC warning impacted JAKi prescribing over the past year; however, this may vary across EU5 markets and risk populations may be small in size. As of Q4 2023, the data suggests that JAKi use among higher risk patients has stabilised throughout the year. REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: None declared.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: